Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...

The tussle between the two drugmakers has spread from the boardroom to the courtroom to the corridors of Washington ...

Oliver Barnes Pfizer and Novo Nordisk duked it out for who will own Metsera — a coveted biotech that’s developing ...

There’s room for more than one winner in this race for GLP-1 weight loss supremacy, but some of these winners are going to be ...

Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s ...

Multiple people across the globe who stepped forward are speaking about what they say is the debilitating aftermath they now ...

Pfizer Inc. (NYSE: PFE) is one of the best undervalued stocks to buy under $50. Pfizer Inc. (NYSE:PFE) received a rating ...

Medicare coverage will cut obesity-drug prices but open the door to millions of new patients.

As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its ...

Pfizer › A strong quarter and earnings beat can sometimes give a stock a big boost. But when that doesn't happen, it usually means there are other factors that are weighing on a business and give ...

That likely only increases the appetite of biotech investors to bet on the next thing. But keep in mind the deal offers some ...

Lower prices for 15 drugs, including Ozempic and Wegovy, are expected to be announced by the end of the month. The price ...